Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Matthieu Allez et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, James Fon, Jessica R. Allegretti et al.|The Lancet. Gastroenterology & hepatology|2026Cited by 6